Skip to main content

REVIEW article

Front. Neurosci.
Sec. Neurodegeneration
Volume 18 - 2024 | doi: 10.3389/fnins.2024.1440334

Stem cell therapy in Alzheimer's disease : current status and perspectives

Provisionally accepted
Chu-Ming Ou Chu-Ming Ou Wei-Wei Xue Wei-Wei Xue Dong Liu Dong Liu Liya Ma Liya Ma Hai-Tao Xie Hai-Tao Xie Ke Ning Ke Ning *
  • Guangdong Celconta Biotechnology, Dongguan, Guangdong,, China

The final, formatted version of the article will be published soon.

    An incurable neurogenerative illness, Alzheimer's disease, is the cause of most global health, medical, and social disasters. The two main symptoms are cognitive impairment and neuronal loss. Current medications that target tau protein tangles and Aβ plaques are not very effective because they only slow the symptoms of AD and do not repair damaged cells. Stem cell-based treatments, however, present an alternative strategy in the treatment of AD.They have the capacity to divide into specialized adult cells, have self-renewal abilities, and multiplication. Stem cells can now be employed as a donor source for cell therapy due to developments in stem cell technology. This review covers preclinical and clinical updates on studies based on targeting the tau protein tangles and Aβ plaque, as well as four types of stem cells employed in AD treatment. The review also outlines the two basic pathologic aspects, tau protein tangles and Aβ plaques, of AD.

    Keywords: Alzheimer's disease, Stem Cell Therapy, Aβ deposits, nFTS, clinical trials

    Received: 29 May 2024; Accepted: 09 Oct 2024.

    Copyright: © 2024 Ou, Xue, Liu, Ma, Xie and Ning. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) or licensor are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.

    * Correspondence: Ke Ning, Guangdong Celconta Biotechnology, Dongguan, Guangdong,, China

    Disclaimer: All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.